Evolutionary Nutrient Sensing Strategy in Prenatal Liver Identified as Critical Safeguard Against Fetal Growth Restriction

New research shows how TRPV4 acetylation in the prenatal liver prevents mTORC1 inhibition, safeguarding fetal development during low-glucose conditions.

By: AXL Media

Published: Mar 14, 2026, 5:57 AM EDT

Source: Information for this report was sourced from Higher Education Press

The Paradox of Fetal Growth in Nutrient Scarce Environments

Throughout prenatal development, the human fetus exists in a biological environment characterized by significantly lower glucose levels compared to those of the mother. Despite this chronic lack of primary fuel, fetal hepatocytes must maintain intense anabolic activity to support the rapid tissue expansion and organ development necessary for a healthy birth. Traditionally, the central metabolic regulator known as mTORC1 is inhibited during low-glucose periods to conserve energy. However, new research identifies a specialized evolutionary adaptation in fetal livers that allows this regulator to remain fully operational, effectively ignoring the low-nutrient signals that would otherwise stall growth.

Mechanistic Bypass of Conventional Metabolic Inhibitions

In adult cells, low glucose levels typically trigger the activation of AMPK, which subsequently inhibits mTORC1 to prevent cellular exhaustion. The study found that while fetal hepatocytes do effectively activate AMPK, they possess a unique bypass mechanism involving the TRPV4 protein. Mechanistically, TRPV4 is an upstream regulator of the mTORC1 pathway. In the fetal liver, this protein undergoes a specific chemical modification where it is acetylated at the K608 position. This modification serves as a molecular shield, preventing the protein from being deactivated by traditional nutrient-sensing molecules.

The Critical Role of TRPV4 Acetylation at K608

The acetylation of TRPV4 at the K608 site is the cornerstone of this adaptive survival strategy. In normal adult metabolism, when glucose is low, a molecule called aldolase becomes "FBP-unoccupied" and inhibits TRPV4, which in turn shuts down the mTORC1 growth engine. However, the acetylated state of TRPV4 in fetal livers blunts this inhibition. This allows the fetus to continue building proteins and lipids even when the mother’s blood sugar is low, ensuring that the developmental timeline remains on track despite external nutritional challenges.